Cherish van Schaik
Family · Choteau, MTNPI 1295164697
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,845 and has fallen 96.8% since, to $58 in 2025. Among family clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$871
- Novo Nordisk$590
- Biohaven Pharmaceuticals, Inc.$347
- Esperion Therapeutics, Inc.$272
- Amgen$180
- Bayer$161
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,65298%
- Education$662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $871 |
| Novo Nordisk | 40 | $590 |
| Biohaven Pharmaceuticals, Inc. | 30 | $347 |
| Esperion Therapeutics, Inc. | 19 | $272 |
| Amgen(2 entities) | 12 | $180 |
| Bayer | 9 | $161 |
| Abbott | 7 | $145 |
| Johnson & Johnson | 6 | $130 |
| Pfizer | 6 | $122 |
| Axsome Therapeutics, Inc. | 4 | $106 |
| Sanofi-aventis U.S. LLC | 5 | $95 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $88 |
| Astellas Pharma US Inc | 4 | $65 |
| AstraZeneca | 4 | $55 |
| Amarin Pharma, Inc. | 3 | $53 |
| Antares Pharma, Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Halozyme Inc | 1 | $35 |
| GSK | 2 | $28 |
| Novartis | 2 | $28 |
| Exact Sciences | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $7 |
How this compares
$3,717 in reported general payments places this provider in the 95th percentile of 481 family providers in Montana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $86,633 |
| Repatha SureclickEvolocumab | 18 | $16,058 |
| EntrestoSacubitril/Valsartan | 19 | $14,349 |
| LinzessLinaclotide | 16 | $11,685 |
| XareltoRivaroxaban | 21 | $10,539 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $8,196 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,286 |
| Levothyroxine Sodium | 45 | $987 |
| Atorvastatin Calcium | 60 | $507 |
| Montelukast Sodium | 53 | $474 |
| Losartan Potassium | 49 | $399 |
| Potassium Chloride | 22 | $285 |
| Prednisone | 52 | $276 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 11 | $261 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $590 | $86,63373 claims |
| NovartisEntresto | $28 | $14,34919 claims |
| AbbVieLinzess | $871 | $11,68516 claims |
| Johnson & JohnsonXarelto | $130 | $10,53921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 family providers in Montana.
Other family in Choteau
- Amanda MurrayGreat Falls$101K
- Kara AddisonHelena$50K
- Lacy TangedahlBillings$31K
- Mara ZelloBozeman$31K
- Michelle Weaver KnowlesMissoula$14K
- Jessica HavensHelena$11K
- Tara WellsHelena$10K
- Sherri NassarBozeman$8K
- Sadra ThomasGreat Falls$7K
- Betsy AkinGreat Falls$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.